Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Orio

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Cancer|December 13, 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancerBrandon A Mahal, Yu-Wei Chen, Roshan V Sethi, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Brachytherapy|March 12, 2014
Placement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planningThomas R Niedermayr, Paul L Nguyen, Yonina R Murciano-Goroff, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Brachytherapy|September 12, 2021
Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statementMartin T King, Mira Keyes, Steven J Frank, et al.
JCO Global Oncology|July 11, 2024
Prostate Cancer Awareness in the Middle East: A Cross-Sectional International StudyMutlay Sayan, Ayfer Ay Eren, Yetkin Tuac, et al.
European Urology Focus|July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Urologic Oncology|May 24, 2017
Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomyDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Cancer|December 13, 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancerBrandon A Mahal, Yu-Wei Chen, Roshan V Sethi, et al.
The American Journal of Medicine|February 4, 2015
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?Brandon A Mahal, Matthew R Cooperberg, Ayal A Aizer, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Brachytherapy|March 12, 2014
Placement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planningThomas R Niedermayr, Paul L Nguyen, Yonina R Murciano-Goroff, et al.
International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate CancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Brachytherapy|September 12, 2021
Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statementMartin T King, Mira Keyes, Steven J Frank, et al.
JCO Global Oncology|July 11, 2024
Prostate Cancer Awareness in the Middle East: A Cross-Sectional International StudyMutlay Sayan, Ayfer Ay Eren, Yetkin Tuac, et al.
European Urology Focus|July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Urologic Oncology|May 24, 2017
Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomyDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Pageof 9